1. Stocks
    2. /
  2. Imugene Limited (ASX: IMU)
    3. /

Imugene Limited (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Imugene Limited (ASX: IMU)
    Latest News

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    Imugene share price surges 8% on 'crucial step forward' in US

    | Bernd Struben

    Imugene is working on products intended to selectively kill tumour cells and activate the immune system against cancer cells.

    Read more »

    Two happy scientists analysing test results.
    Healthcare Shares

    'Market will see the value' in Imugene share price

    | Mitchell Lawler

    Imugene shares might be in a slump, but the CEO is not giving up now.

    Read more »

    three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
    Share Gainers

    Why Bell Financial, Downer, Imugene, and Vulcan shares are pushing higher

    | James Mickleboro

    These ASX shares are ending the week on a positive note.

    Read more »

    Young businessman standing on the top of the mountain punching fist in the air.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a top day for ASX investors on Wednesday.

    Read more »

    Three rockets heading to space
    Share Gainers

    3 ASX All Ordinaries shares surging more than 10% today

    | Bernd Struben

    These three ASX All Ordinaries shares are trouncing the benchmark index today.

    Read more »

    A scientist examining test results.
    Opinions

    Down 35% in a year, is the Imugene share price a buying opportunity right now?

    | Mitchell Lawler

    Is a 35% discount enticing enough to invest in this clinical-stage biotech. Here's my take.

    Read more »

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Did you own the mining stock that outperformed the rest of the ASX 200 on Friday?

    Read more »

    three businessmen high five each other outside an office building with graphic images of graphs and metrics superimposed on the shot.
    Share Gainers

    Why Boral, Imugene, Nickel Industries, and Sigma shares are rising today

    | James Mickleboro

    These ASX shares are having a strong finish to the week.

    Read more »

    Three young people in business attire sit around a desk and discuss.
    Share Market News

    3 All Ords stocks making major moves on big news today

    | Brooke Cooper

    Let's dive into today's news from the All Ordinaries trio.

    Read more »

    Two fists connect in a surge of power, indicating strong share price growth or new partnerships for ASC mining and resource companies
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    It was a great day to be invested in this ASX 200 energy stock.

    Read more »

    A woman looks distressed as she stares dramatically at her phone
    Share Fallers

    Why Allkem, Argosy Minerals, Audio Pixels, and Imugene shares are falling

    | James Mickleboro

    These ASX shares are having a tough time on Thursday.

    Read more »

    A woman wearing yellow smiles and drinks coffee while on laptop.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Brooke Cooper

    Guess which ASX 200 stock defied today's downturn to gain 4.8%.

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Limited

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    Profile

    since

    Note